DISCOVER THE MODERN FACE OF ACTINIC KERATOSIS FIELD THERAPY
Learn MorePrescribe KLISYRI®—available in a 350 mg packet size for a larger treatment area, up to 100 cm2
The efficacy, tolerability, treatment satisfaction, and compliance you expect1-6
AK Clearance1,2
See before and after photos of real patients with AK treated with KLISYRI®
See before and after photos of real patients with AK treated with KLISYRI®
after photos
DEMONSTRATED SAFETY AND TOLERABILITY1,2
A low rate of severe local skin reactions, with severe reactions occurring in less than 10% of patients1,2
assessment
CONCORDANT PATIENT AND CLINICIAN TREATMENT SATISFACTION3,4
Explore outcomes from a real-world study
outcomes
99% PATIENT COMPLIANCE5,6
Compliance to the 5-day self-application treatment regimen was >99%5,6
5-day dosing
Broad payer
coverage7
Learn more about
affordable access
and
patient savings
Helpful resources for you and your patients
Explore informative
materials to support
your patients
Hear why real-world physicians are prescribing KLISYRI®
view video galleryHear why real-world physicians are prescribing KLISYRI®
view video galleryThe importance of treating AK
1 in 10 lesions will turn out to be cancerous—but there's no way to predict which AK will progress8,9
Approximately 65% of squamous cell carcinomas (SCCs) evolve from untreated AK lesions10
The risk of SCC progression in patients with multiple AK lesions can be as high as 80%11
Modernizing the management of AKs
A positive AK field therapy experience may have a positive impact on patient compliance—resulting in improved clinical outcomes.12,13
IMPORTANT SAFETY INFORMATION
INDICATION
KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Ophthalmic Adverse Reactions
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local Skin Reactions
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
Please see full Prescribing Information.
To report an adverse event or product complaint, call or email Medical Affairs and Customer Relations • Phone: 1-866-665-2782• Fax: 510-595-8183 •
Email: almirallmc@eversana.com
References: 1. KLISYRI®. Prescribing information. Almirall, LLC. 2. Blauvelt A, Kempers S, Lain E, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384:512-520. 3. Schlesinger T, Kircik L, Lebwohl M, et al. Patient- and clinician-reported outcomes for tirbanibulin in actinic keratosis in clinical practice across the United States (PROAK). J Drugs Dermatol. 2024;23(5):338-346. doi:10.36849/JDD/8264 4. Data on File. 2023. PROAK Study Final Report. 5. Data on file. 2019. KX01-AK-003. 6. Data on file. 2019. KX01-AK-004. 7. Breakaway Partners. Data accessed October 28, 2023, and current as of that date. Coverage is subject to change. 8. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007;33(9):1099-1101. 9. Schmitz L, Kahl P, Majores M, et al. Actinic keratosis: correlation between clinical and histological classification systems. JEADV.2016;30(8):1303-1307. 10. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115(11):2523-30. doi: 10.1002/cncr.24284 11. Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther. 2014;4(1):11-31. 12. Marson J, Del Rosso J, Bhatia N, et al. Considerations in the management of actinic keratosis: the importance of adherence and persistence to therapy. Skin J Cutan Med. 2021;5(2):83-89. 13. Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. JEADV. 2017;31(suppl 2):17-20.